{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is Corvus Pharmaceuticals, Inc. technically bullish or bearish?
As of June 18, 2025, the trend is mildly bullish with some supportive indicators, but caution is advised due to mixed signals from the MACD and moving averages.
Who are in the management team of Corvus Pharmaceuticals, Inc.?
As of March 2022, the management team of Corvus Pharmaceuticals, Inc. includes Mr. Richard Miller (Chairman, President, and CEO) and Dr. Edith Mitchell (Director), along with Independent Directors Mr. Ian Clark, Mr. Elisha Gould, Dr. Linda Grais, and Mr. Steve Krognes.
What does Corvus Pharmaceuticals, Inc. do?
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. As of March 2025, it has a market cap of $303.83 million and reported a net profit of $15 million.
How big is Corvus Pharmaceuticals, Inc.?
As of Jun 18, Corvus Pharmaceuticals, Inc. has a market capitalization of 303.83 million, with net sales of 0.00 million and a net profit of -41.40 million over the last four quarters. The company reported shareholder's funds of 32.57 million and total assets of 68.91 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
